(Q38242116)

31 August 2017

title

An update on the management of hepatitis C virus-related arthritis (English)

1 reference

31 August 2017

hepatitis C virus

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Pietro Leccese

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

3

Salvatore D'Angelo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

6

Ignazio Olivieri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Carlo Palazzi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Emilio D'Amico

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

English

0 references

publication date

22 August 2014

1 reference

Expert Opinion on Pharmacotherapy

31 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

2039-2045

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Immunological alterations in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Hepatitis C virus and arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

The case for hepatitis C arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Management of hepatitis C virus-related arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Hepatitis C virus infection in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Hepatitis C virus-related arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Hepatotoxicity associated with non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Old and new antirheumatic drugs and the risk of hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Anti-inflammatory drugs and variceal bleeding: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Effects of corticosteroids on HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Hepatitis C and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Diverse Effects of Cyclosporine on Hepatitis C Virus Strain Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

B-cell therapies in established rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Rituximab-based treatment, HCV replication, and hepatic flares

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Hepatitis C treatment: an incipient therapeutic revolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2014.946404

10.1517/14656566.2014.946404

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25146875%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference